Market Overview - The Shanghai Composite Index closed at 4085.77 points, up 0.05%, with a trading volume of 11,974 billion yuan [1] - The Shenzhen Component Index closed at 14,030.56 points, up 0.06%, with a trading volume of 16,567.97 billion yuan [1] - The ChiNext Index closed at 3,329.69 points, up 0.31%, with a trading volume of 7,632.51 billion yuan [1] - The STAR Market 50 Index closed at 1,443.39 points, up 0.99%, with a trading volume of 871 million yuan [1] - The total trading volume of both markets was 28,541.97 billion yuan, an increase of 475.91 billion yuan compared to the previous trading day [1] Sector Performance - Strong sectors included coal, electronics, telecommunications, power equipment, pharmaceutical biology, construction decoration, steel, and machinery equipment [2] - Weak sectors included oil and petrochemicals, securities, beauty care, education, banking, and precious metals [2] - The top-performing stocks were concentrated in electronics, machinery equipment, chemicals, telecommunications, and pharmaceutical biology [2] Individual Stock Performance - 2,078 stocks rose, while 3,003 stocks fell, with 93 stocks remaining flat and 9 stocks suspended [2] - Among the stocks with the most consecutive daily limits, Victory Energy led with 14 consecutive limit-ups [4] - 110 stocks saw net inflows exceeding 100 million yuan, with Aerospace Development receiving the highest net inflow of 1.933 billion yuan [8][9] Fund Flow Analysis - The net outflow of main funds in the Shanghai and Shenzhen markets was 47.198 billion yuan, with the ChiNext seeing a net outflow of 17.043 billion yuan [5] - Seven sectors experienced net inflows, with the telecommunications sector seeing the highest inflow of 2.814 billion yuan [5] - The defense industry had the largest net outflow of 8.7 billion yuan, followed by computer, automotive, electronics, and power equipment sectors [5] Institutional Activity - Institutions had a net buy of 2.12 billion yuan, with the highest net buy in Sanbo Brain Science at approximately 266.27 million yuan [14][15] - The most sold stock by institutions was Goldwind Technology, with a net sell of approximately 406.44 million yuan [14][15]

资金面上看，今日脑机接口概念板块获主力资金净流出63.09亿元，其中，52股获主力资金净流出，18 股主力资金净流出超亿元，净流出资金居首的是海格通信，今日主力资金净流出19.34亿元，净流出资 金居前的还有三博脑科、科大讯飞、汉威科技等，主力资金分别净流出6.85亿元、5.34亿元、4.49亿 元。今日主力资金净流入居前的概念股有岩山科技、创新医疗、南京熊猫等，主力资金分别净流入7.69 亿元、1.80亿元、9067.99万元。（数据宝） 脑机接口概念资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002465 | 海格通信 | 2.05 | 24.69 | -193361.27 | | 301293 | 三博脑科 | 10.45 | 46.31 | -68511.28 | | 002230 | 科大讯飞 | -1.61 | 3.78 | -53387.32 | | 300007 | 汉威科技 | -3.84 | 18.84 | -44932.57 | | 000516 | 国际医学 ...

格隆汇1月7日｜三博脑科今日涨10.45%，成交额68.62亿元，换手率46.31%，盘后龙虎榜数据显示，深 股通专用席位买入3.41亿元并卖出1.65亿元，4家机构专用席位净买入2.66亿元。 ...

证券之星消息，1月7日医疗服务板块较上一交易日上涨1.7%，益诺思领涨。当日上证指数报收于 4085.77，上涨0.05%。深证成指报收于14030.56，上涨0.06%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688710 | 益诺思 | 55.31 | 20.00% | 5.97万 | | 3.17亿 | | 688222 | 成都先导 | 30.44 | 13.67% | 44.49万 | | 13.43亿 | | 301293 | 三博脑科 | 93.82 | 10.45% | 74.53万 | | 68.62亿 | | 002173 | 创新医疗 | 28.63 | 9.99% | 10.16万 | | 2.91亿 | | 688621 | 阳光诺和 | 72.10 | 7.77% | 6.88万 | | 4.95 乙 | | 603127 | 昭衍新药 | 41.30 | 7.41% | 36.68万 | | 14.97亿 | | ...

每经AI快讯，1月7日，三博脑科（301293）今日涨10.45%，成交额68.62亿元，换手率46.31%，盘后龙 虎榜数据显示，深股通专用席位买入3.41亿元并卖出1.65亿元，4家机构专用席位净买入2.66亿元。 ...

Group 1 - The stock of Sanbo Brain Science increased by 10.45% today [1] - The trading volume reached 6.862 billion yuan, with a turnover rate of 46.31% [1] - Data from the post-market dragon and tiger list indicates that the Shenzhen Stock Connect special seat bought 341 million yuan and sold 165 million yuan, resulting in a net purchase of 266 million yuan by four institutional special seats [1]

2026年A股开门红，脑机接口相关概念股均迎来暴涨。 自1月5日开始，三博脑科（301293）、翔宇医疗、美好医疗（301363）、伟思医疗、诚益通（300430） 等股票连续多个交易日出现20%涨停，冠昊生物（300238）、塞力医疗（603716）、创新医疗 （002173）、南京熊猫（600775）、岩山科技（002195）等也都连续10%涨停。截至1月7日记者发稿， 脑机接口板块依然涨停不断。 多重利好消息传来 消息面上，埃隆.马斯克近日表示，旗下脑机接口公司Neuralink将于2026年开始大规模生产脑机接口设 备，并将同步推进流程高度精简、几乎完全自动化的外科手术方案。这一表态更是引发脑机接口相关概 念股热度快速攀升。有消息称，量产后，脑机单台植入手术的成本将从百万美元降至10万美元以内，全 自动化落地后有望进一步下探至5万美元区间，为日后脑机接口设备的大规模商业化埋下伏笔。 国内政策层面，2025年7月，工业和信息化部、国家发展改革委、教育部、国家卫生健康委、国务院国 资委、中国科学院、国家药监局七部门联合印发《关于推动脑机接口产业创新发展的实施意见》（以下 简称《意见》），首次系统性地明确了 ...

1月7日，三博脑科（301293.SZ）断板，早盘涨幅一度收窄近2%，随后强势拉升，维持震荡走势，截至 午间收盘，报94.57元/股，涨11.34%，成交额为57.3亿元，总市值为195亿元。 消息面上，1月6日晚，三博脑科发布异动公告，称公司目前不涉及脑机接口产品的研发、生产及销售， 神经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响。 此前，受脑机接口设备量产等消息刺激，脑机接口板块掀起涨停潮。作为脑机接口概念股，三博脑科在 1月5日、1月6日均收获20cm涨停。期间，21财经《辟谣财知道》注意到，有网络帖文称其为"国内唯一 获批脑机接口临床植入许可的民营医院集团，累计完成300例脑机手术"，相关帖文被AI抓取到券商软件 的个股涨停分析后广泛传播。 对此，21财经·南财快讯记者以投资者身份致电三博脑科，接线工作人员回应称，已关注到相关帖文， 对于"国内唯一获批脑机接口临床植入许可的民营医院集团"这一说法，"据我这边了解应该不是，这些 信息应该是好多个东西杂糅在一起的"；而对于"完成300例脑机手术"，该工作人员澄清，"这个是假消 息"。 值得注意的是，前述澄清并不意味着三博脑科就脱离了脑 ...

Core Viewpoint - Sanbo Brain Science (301293.SZ) experienced a significant stock fluctuation, initially narrowing its gains by nearly 2% before rebounding strongly, maintaining a volatile trading pattern. The stock had previously hit the daily limit of 20% on January 5 and 6 due to speculation surrounding its status in the brain-computer interface sector [1]. Group 1 - Sanbo Brain Science is identified as a brain-computer interface concept stock, which has attracted attention due to its recent stock performance [1]. - The company has been the subject of online rumors claiming it is the "only private hospital group in China approved for clinical implantation of brain-computer interfaces," and that it has completed 300 brain surgeries [1]. - A representative from Sanbo Brain Science clarified that the claim regarding being the "only approved private hospital group" is inaccurate and that the information circulating is a mix of various details [1]. Group 2 - The company also denied the claim of having completed 300 brain surgeries, labeling it as false information [1].

三博脑科 20260106 摘要 三博脑科前三季度净利润同比下降 20%，主要受去年同期非经常性利润 增加及新院区运营成本上升影响，但预计全年仍能完成年初目标。昆明 和西安新院区分别于 2025 年二季度和 9 月开业，虽初期受医保政策影 响收入有限，但运营情况乐观，为未来发展奠定基础。 三博脑科积极布局脑机接口技术，将其视为未来产业方向，并坚持医教 研一体化发展。公司通过临床需求端探索新技术产品，与清华大学联合 成立实验室，设立基金，投资 AI 脑电分析和柔性电极项目，推动技术与 产业结合。 三博脑科神经系统疾病治疗主要包括急诊创伤、功能神经疾病、颅脑肿 瘤和慢性病，占比分别为 20%、30%、50%。公司通过早期产品开发、 中期投资与股权合作、后期产品应用形成全链条布局，推动技术品牌与 业务产业协同。 面对民营医院的经营压力，三博脑科凭借完善的管理体系和技术品牌优 势，专注于神经外科为主的医疗服务，并优化新开院区运营，力求扭亏 为盈。脑机接口手术作为高风险四级手术，定价参照神经外科标准，耗 材费用另计，短期内允许自主定价。 Q&A 请介绍一下三博脑科在 2025 年度的经营情况以及业绩表现。 2025 年 ...